Chief Executive Officer

Dr. Sherif joined Oculis as Chief Executive Officer in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund. Since his arrival, the company raised over $100M USD, two successful Phase 2b trials were completed with OCS-01, a positive end-of-phase 2 meeting was conducted with the FDA propelling OCS-01 into Phase 3 for two distinct indications, the OPTIREACH® formulation technology was validated for both: the back- and the front-of-the-eye, and OCS-02, an antibody fragment anti-TNF alpha, was in-licensed from Novartis.


Prior to this, he held senior global positions in both Alcon, where he was President of Europe, Middle East and Africa, and Novartis, where he served as President of Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles as Head of Transplant and Infectious Disease for Latin America, and President of the Novartis Vaccines and Diagnostics Division for Latin America. During his tenure in Canada and in Europe, he held several Chairman and Co-chair positions such as Vice Chairman for the Innovative Medicine Canada Association in Ottawa, Chairman of In-Vivo Montreal and Chairman of the Board Ophthalmic Surgery and Vision Care at Eucomed, Brussels.


Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a Specialized Master’s Degree in Medical Management.

Vice-President, Clinical Operations

Ms Allman is a highly accomplished Project Leader with over 23 years of global clinical trial management experience. Prior to joining Oculis, Ms Allman was a Senior Project Leader at Parexel, a renowned Clinical Research Organisation in the field of Ophthalmologywhere she undertook several leadership roles and worked alongside a wide range of leading pharmaceutical companies. While at Parexel, Ms Allman played a key role for Oculis in the successful delivery and completion of the DX-211 study with OCS-01. From an educational perspective, she holds a Bachelor of Science in Applied Statistics from Sheffield Hallam University in England.

Vice President of Pharmaceutical Development

Gudrun M. Asgrimsdottir joined Oculis in 2010 from GlaxoSmithKline in Reykjavik where she served as Business Unit Manager. Since joining Oculis, Ms. Asgrimsdottir has had management roles, currently holding the position of VP Pharmaceutical Development. Ms. Asgrimsdottir received a M.Sc. degree in pharmacy from the University of Iceland in 1997. Upon completing her studies, Ms. Asgrimsdottir joined the R&D department of Omega Farma ehf. where she was primarily responsible for analytical method development. In year 2000 she worked for GlaxoWellcome in the UK. Ms. Asgrimsdottir had the role of a clinical pharmacist in the UK for 4 years and did a diploma in hospital pharmacy from University of London in 2004. Ms. Asgrimsdottir is a co-author of 8 published papers in peer reviewed journals.

MD, Ph.D.
Chief Medical Officer and Head of Portfolio Management

Dr. Chang brings to Oculis more than 20 years of global experience in medical and regulatory affairs, clinical development, health economics and market access. She joins Oculis from Novartis where she spent the last 13 years in various senior leadership roles in both the US and China. At Novartis, Dr. Chang led the Global Medical Affairs team where she provided strategic oversight for the ophthalmology portfolio, including retinal, Gene Therapy and ocular surface disease.
Before this Dr. Chang served as Head of Clinical Development & Medical Regulatory Affairs in North America at Alcon where she oversaw all strategic, medical, and scientific aspects of clinical development. She was also Chief Medical Officer and Vice President of Medical Affairs in Greater China at Novartis where she established medical organization and provided strategic insights regarding medical, clinical and industry trends and growth opportunities in China.
Prior to Novartis, Dr. Chang held various senior roles in health economics, strategic marketing and clinical development at key global pharmaceutical companies including Bayer, Aventis, Johnson & Johnson and Abbott Laboratories.
Dr. Chang gained her Doctor of Medicine from Wuhan University and has further completed the post-doctoral fellowship in Johns Hopkins and a Ph.D. at the University of Maryland Baltimore.

Chief Financial Officer (CFO)

Ms. Cheung has 20 years of financial and general management experience at emerging growth life science companies. She joins Oculis from the NASDAQ-listed company Anika Therapeutics, Inc. where she was CFO from 2013 to 2020. During her tenure, she played a vital role in redefining and executing the company’s mission, vision and long-range financial-operational targets; supported and enabled U.S. launches of key therapeutics products; and executed on three strategic acquisitions. Prior to Anika, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Ms. Cheung began her career in the technology audit practice at PricewaterhouseCoopers. She holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as CPA in Massachusetts.

Vice President of Strategic Mk, Business Development and Licensing

Mrs. Gauthier has 18 years of operational experience across a diverse range of therapeutic areas and healthcare sectors. She joined Oculis in 2018 from Pharmascience, where she was Commercial Head for Pendopharm, branded products division of Canadian based Pharmascience. Prior to Pharmascience, Mrs. Gauthier spent more than 10 years with Novartis Canada where she held several commercial positions of increasing responsibility, culminating in National Sales Associate Director. Her consolidated experience and knowhow span over complimentary disciplines – sales, marketing, market access, analytics, business development, and communication, providing her with a 360 ° overview of commercialization. She holds a Bachelor of Business Administration degree in Finance and Marketing from the University of Quebec in Montreal, an M.Sc. in Administration specialized in marketing from HEC Montreal, where she returned as lecturer. She was also certified in 2014 as Project Management Professional (PMP) by the Project Management Institute. Strong advocate for social involvement and believing in giving back to the community, Mrs Gauthier takes great pride in being one of the five founding members of Women Leaders in Pharma, association which aims at empowering women in the pharmaceutical industry; she also held different roles on committees and as a volunteer. She currently serves as a non-executive member of the EPFL Innovation Park Foundation Board.

Oculis Pharma, Grandagarður 16. Fyrirtækið er að gera sniðuga hluti með augndropa.
Chief Strategy Officer

Mr. Jóhannesson joined Oculis in 2015 from Straumur Investment Bank where he served as Managing Director Corporate Finance. Prior to joining Straumur in 2015, he worked for Islandsbanki, and its predecessor Glitnir Bank, in Corporate Finance and Business Development. He has broad sector experience, having managed and advised on transactions within multiple industries, including pharmaceuticals, venture capital, energy, financials, and various manufacturing industries. Mr. Jóhannesson’s transaction experience includes, IPOs, private placements, M&A and restructurings. Mr. Jóhannesson has a B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil in Management Science from the University of Cambridge and is a certified securities broker in Iceland.

MSc. MPharm, Ph.D.
Chief Research and Technology Officer,
Dr. Loftsson is a leading scientist in the field of nanoparticle drug delivery, in particular cyclodextrin-based formulations. He has served as an advisor to many of the global pharmaceutical companies on drug formulations and IP rights. Dr. Loftsson co-founded and served as CEO of the biotechnology company Cyclops ehf. from 1994 until it was acquired by DeCode Genetics in 2000. At that time, he also took on the role of scientific advisor at Decode Genetics, until 2004. Dr. Loftsson received an MS degree in Pharmacy from the University of Copenhagen, School of Pharmaceutical Sciences and MS and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas, Department of Pharmaceutical Chemistry. He has served as Assistant, Associated and full Professor on the Faculty of Pharmaceutical Sciences, University of Iceland for over 35 years. Dr. Loftsson has authored and co-authored more than 220 peer-reviewed papers in addition to a couple of books and a number of book chapters. He is a fellow of the AAPS and is on the editorial boards of the Journal of Pharmaceutical Sciences, International Journal of Pharmaceuticals, Journal of Drug Delivery Science and Technology, Die Pharmazie, and the Journal of Pharmacy and Pharmacology. In 2014, Dr. Loftsson was recognized as one of the World’s Most Influential Scientific Minds by Thomson Reuters.
Marc Maderi Photo
Vice President,
Quality Assurance
Mr. Maderi joined Oculis in 2021, from Santen, a key player in Ophthalmology, where he was Head of Quality EMEA. Prior to Santen, he held several Global Quality Assurance and Management position from the Biotech, Pharma and Devices industries. He brings in expertise covering product life cycle from R&D to commercialization. Mr. Maderi worked at GSK, Ferring and BBraun where he oversaw and led quality over product development, commercial regions and manufacturing for sterile and non-sterile products.  Mr. Maderi received an executive MBA from the University of Geneva and an MSc in Chemical Engineering from EPFL.
Vice President, Technology & Pharmaceutical Sciences

Dr. Pilotaz joins Oculis with more than 20 years’ experience in innovation of global sterile health products in both pharmaceutical and medical device industries, including 15 years in the Ophthalmology sector specifically. Most recently, he was Senior Director and Head of CMC and Pharmaceutical Operations at Nicox S.A. in charge of several outstanding ophthalmic development projects for the USA market. He has previously worked for Becton Dickinson and Laboratoires Thea with multiple incremental leadership positions in the R&D field.

Dr. Pilotaz completed a doctorate degree in pharmacy from the Grenoble school of pharmacy and he has a noteworthy experience in both intellectual property, project management, device design and marketing. He has an extensive track record in sterile drug design, development, industrialization and registration. He is co-author in 5 formulation patents for topical ophthalmic drugs and successfully contributed to multiple drugs commercialized in both Europe and USA.